Spectratox Drug Phototoxicity Collaboration Celebrates 25 Years
The staffs of Chiltern International Limited (Chiltern), a global contract research organization (CRO), and Spectratox Limited, celebrate the 25 year mark of their successful collaboration in Drug Phototoxicity.
Chiltern Early Phase and Spectratox have worked together using a validated and regulatory accepted in vivo human study method for the assessment of drug phototoxicity. The history of this collaboration can be traced through their multiple publications in peer reviewed journals.
“The success story of this methodology is not just measured in publications,” stated Dr Brian Sanderson, Medical Director, Chiltern Early Phase. “It is measured in the success we have had in helping new drugs continue their developmental journey for areas of therapeutic need.”
Professor James Ferguson, Head of the Academic Department of Dermatology, University of Dundee, and CEO of Spectratox, explained, “The evolution of randomized controlled trials has been in response to industry and regulatory requirements. Our trials, which tend to be conducted prior to Phase III, produce data that defines the phototoxic risk in man in terms of severity and causal wavelengths as well as providing an understanding of the likelihood of ocular phototoxicity. Where phototoxicity is found, advice on protective measures to enable future development of the compound is an important aspect of our work.”
Dr Sanderson added, “New study designs have been introduced to act as initial “screening” in man for drugs with potential phototoxicity. The new designs have evolved in response to the growing demand to assess this earlier in clinical drug development. The benefits are savings in both time and cost whilst remaining scientifically robust.”
Glenn Kerkhof, Chiltern CEO, commented, “This 25 year collaboration is cause for celebration when we look back and realize the successes reached as well as what is presently being accomplished together. We very much look forward to what the next 25 years will bring in advancing drug development processes.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
